Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AbbVie Inc. Director's Dealing 2025

Mar 10, 2025

29755_dirs_2025-03-10_75481ec7-74d9-40ee-80fe-6bb5e48874b8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2025-03-01

Reporting Person: Purdue David Ryan (N/A)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock, $0.01 par value 4505 Direct
Common Stock, $0.01 par value 527 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option (Right to buy) $149.62 2033-02-15 Common Stock (3376) Direct
Option (Right to buy) $175.28 2034-02-14 Common Stock (5358) Direct
Option (Right to buy) $192.86 2035-02-12 Common Stock (5208) Direct

Footnotes

F1: Balance in AbbVie Savings Program as of March 1, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature.

F2: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program. The option became exercisable as to 1,126 shares on 02/16/2024, as to 1,125 shares on 02/16/2025, and will become exercisable as to 1,125 shares on 02/16/2026.

F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program. The option became exercisable as to 1,786 shares on 02/15/2025, and will become exercisable as to 1,786 shares on 02/15/2026, and as to 1,786 shares on 02/15/2027.

F4: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program. The option becomes exercisable as to 1,736 shares on 02/13/2026, as to 1,736 shares on 02/13/2027, and as to 1,736 shares on 02/13/2028.